匹多莫德对过敏性紫癜复发的预防作用及安全性评估  

Evaluation on Effect and Safety of Pidotimod in Preventing Recurrence of Allergic Purpura

作　　者：钟婕[1] 陈胜利[1] 许博[1] 王琴[1] 高海燕[1] 

机构地区：[1]广东省东莞市厚街医院儿科,523945

出　　处：《中华全科医学》2013年第4期552-553,共2页Chinese Journal of General Practice

摘　　要：目的探讨匹多莫德对过敏性紫癜复发的预防作用及安全性。方法选取2008年7月-2011年6月于东莞市厚街医院进行治疗的72例过敏性紫癜患者为研究对象,将其随机分为对照组(常规治疗组)和观察组(加用匹多莫德组)每组各36例,后将两组患者3个月、6个月、1年的复发率、不良反应发生率及治疗前、治疗后1个月、3个月的外周血T淋巴细胞亚群及血清P选择素、IFN-γ水平进行比较。结果观察组3个月、6个月、1年的复发率均低于对照组,治疗后1个月、3个月的外周血T淋巴细胞亚群及血清P选择素、IFN-γ水平改善幅度均大于对照组,P均<0.05,差异均有统计学意义,而两组不良反应发生率差异无统计学意义,P>0.05。结论匹多莫德可有效预防过敏性紫癜的复发,且安全性较高。Objective To investigate the effect and safety of Pidotimond in preventing the recurrence of allergic purpura.Methods Total 72 patients with allergic purpura in our hospital from July 2010 to June 2011 were selected as research object,and they were randomly divided into control group（routine treatment group） and observation group（Pidotimod group） with 36 cases in each group,then the recurrence rate in three months,six months and one year,the incidence of adverse reactions,Peripheral blood T lymphocyte subsets,serum P-selectin,IFN-γ before the treatment and one month and third month late were compared between the two groups.Results The recurrence rate of observation group in three months,six months and one year were all lower than those of the control group,the improvement of Peripheral blood T lymphocyte subsets,serum P-selectin,IFN-γ one and third month after the treatment were all higher than those of the control group,all P0.05,there were significant differences,but the two groups′ incidence of adverse reactions had no significant differences,P0.05.Conclusion The Pidotimod can effectively prevent the recurrence of allergic purpura,and its safety is higher.

关 键 词：匹多莫德 过敏性紫癜 复发 预防 安全性 

分 类 号：R554.6[医药卫生—血液循环系统疾病] R593.1[医药卫生—内科学]